147769-93-5

Basic information

• Product Name: (S)-3-Methyl-1-(2-piperidin-1-ylphenyl)butylamine
• Synonyms: (S)-[A-(2-methylpropyl)-2-(1-piperidinyl)benzene-methanamine;(S)-3-METHYL-1-[2-(1-PIPERIDINYL)PHENYL]-BUTYLAMINE;Repaglinide Intermediate 1;Repaglinide intermediate 4;(S)-3-Methyl-1-(2-piperidin-1-ylphenyl)butylamine;Benzenemethanamine, .alpha.-(2-methylpropyl)-2-(1-piperidinyl)-, (.alpha.S)-;(S)-3-Methyl-1-(2-piperidine-1-yl-phenyl)-butylamine;(αS)-α-(2-Methylpropyl)-2-(1-piperidinyl)-benzenemethanamine
• CAS NO: 147769-93-5
• Molecular Formula: C16H26N2
• Molecular Weight: 246.39
• EINECS: 1312995-182-4
• Product Categories: Pharmaceutical material and intermeidates
• Mol File: 147769-93-5.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 370.5 °C at 760 mmHg
• Flash Point: 164.7 °C
• Appearance: /
• Density: 0.99 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.539
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 10.20±0.10(Predicted)
• CAS DataBase Reference: (S)-3-Methyl-1-(2-piperidin-1-ylphenyl)butylamine(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-3-Methyl-1-(2-piperidin-1-ylphenyl)butylamine(147769-93-5)
• EPA Substance Registry System: (S)-3-Methyl-1-(2-piperidin-1-ylphenyl)butylamine(147769-93-5)

Safety Data

• Hazardous Substances Data: 147769-93-5(Hazardous Substances Data)

Usage

General Description

(S)-3-Methyl-1-(2-piperidin-1-ylphenyl)butylamine, also known as 3-MPBA, is a chemical compound with a molecular formula C15H24N2. It is an organic compound that belongs to the class of amines and is derived from benzaldehyde. 3-MPBA is commonly used as a chiral building block for the synthesis of pharmaceuticals and other organic compounds. It is a white solid at room temperature and has a melting point of around 54-56°C. 3-MPBA is known for its ability to interact with neurotransmitter receptors in the brain, making it a potential candidate for the development of new drugs targeting neurological disorders and mental health conditions.

InChI:InChI=1/C16H26N2/c1-13(2)12-15(17)14-8-4-5-9-16(14)18-10-6-3-7-11-18/h4-5,8-9,13,15H,3,6-7,10-12,17H2,1-2H3/t15-/m0/s1

Upstream product

• 147769-98-0 N-acetyl-N-<(S)-3-methyl-1-(2-(1-piperidinyl)phenyl)-1-butyl>-amine 
• 89-98-5 2-chloro-benzaldehyde 
• 110-89-4 piperidine 
• 446-52-6 2-Fluorobenzaldehyde 
• 6630-33-7 ortho-bromobenzaldehyde 
• 799255-58-6 C₂₃H₃₂N₂ 
• 590-86-3 isovaleraldehyde 
• 82212-00-8 1-(2-bromophenyl)piperidine 
• 34595-26-1 2-(piperidin-1-yl)benzaldehyde 
• 1098066-89-7 (S)-3-methyl-1-(2-piperidino-phenyl)-1-butylamine di-p-toluoyl-D-tartaric acid salt 
• 108157-52-4 (S)-1-(2-piperidino-phenyl)-3-methyl-1-butylamine 
• 1026508-90-6 [3-Methyl-1-(2-piperidin-1-yl-phenyl)-but-3-enyl]-[1-(2-piperidin-1-yl-phenyl)-meth-(E)-ylidene]-amine 

Downstream Products

• 147770-06-7 (S)-(+)-ethyl 2-ethoxy-4-<2-<<3-methyl-1-<2-(1-piperidinyl)phenyl>butyl>amino>-2-oxoethyl>-benzoate 
• 147769-98-0 N-acetyl-N-<(S)-3-methyl-1-(2-(1-piperidinyl)phenyl)-1-butyl>-amine 
• 135062-02-1 (S)-repaglinide 
• 1098066-88-6 2-ethoxy-N-[(1S)-3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]-4-[2-[[(1S)-3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]benzamide 
• 147770-08-9 (R)-(-)-ethyl 2-ethoxy-4-<2-<<3-methyl-1-<2-(1-piperidinyl)phenyl>butyl>amino>-2-oxoethyl>-benzoate 
• 219921-93-4 (R)-3-methyl-1-(2-(1-pieridinyl)phenyl)-butylamine 

Relevant articles and documents

Synthesis process of hypoglycemic drug repaglinide

The invention discloses a synthesis process of a hypoglycemic drug repaglinide. The process comprises the following steps: a) by using a compound II (S,S')-3-methyl-1-(2-piperidinophenyl)butylamine asa raw material, dissociating with an alkali, and directly condensing the obtained organic phase containing a compound III repigine with a compound IV 3-ethoxy-4-ethoxycarbonyl phenylacetic acid in the presence of an acylation reagent and an alkali without concentration; b) refining the compound V repaglinide ester crude product obtained after condensation by using an alkane solvent; and c) hydrolyzing in the presence of an alcohol solvent and an inorganic alkali, carrying out acidifying of post-treatment at a proper temperature, and purifying the obtained compound I repaglinide crude productby using an alcohol-water mixed solvent to obtain a repaglinide fine product. The synthesis process provided by the invention simplifies the synthesis steps, has the advantages of environmental protection, simple operation, high yield, low cost and the like, and is a repaglinide synthesis process suitable for industrial large-scale production.

Preparation method for (S)-(+)-1-(2-piperidine phenyl)-3-methyl n-butylamine

The invention provides a preparation method for (S)-(+)-1-(2-piperidine phenyl)-3-methyl n-butylamine. The method comprises process steps as described in the specification. According to the invention, the (S)-(+)-1-(2-piperidine phenyl)-3-methyl n-butylamine is synthesized with 3-methyl-1-(2-piperidine phenyl)-1-butanone as a raw material by using a catalytic asymmetric synthetic method. The synthetic method provided by the invention has the advantages of easily-available raw materials, short synthetic route and high yield.

Studies on diastereofacial selectivity of a chiral tert-butanesulfinimines for the preparation of (S)-3-Methyl-1-(2-piperidin-1-yl-phenyl)butylamine for the synthesis of repaglinide

A new method for the asymmetric synthesis of a series of chiral amines including (S)-3-methyl-1-(2-piperidin-1-yl-phenyl)butylamine (2a) a key intermediate to prepare antidiabetic drug repaglinide by using Ellman's reagent tert-butanesulfinamide. Diastereoselective addition of organometallic reagents to t-butanesulfinimines and followed by acidic and basic treatment. The obtained chiral amines were characterized by NMR, MS and other analytical data.